| 31. |
- Jost, W. H., et al.
(author)
-
King’s Parkinson’s Disease Pain Scale : Interkulturelle Adaption in deutscher Sprache
- 2018
-
In: Nervenarzt. - : Springer Science and Business Media LLC. - 0028-2804. ; 89:2, s. 178-183
-
Journal article (peer-reviewed)abstract
- Background: Pain is a frequent symptom of idiopathic Parkinson’s disease and has a substantial impact on quality of life. The King’s Parkinson’s disease pain scale (KPPS) has become internationally established and is an English-language, standardized, reliable and valid scale for evaluation of pain in idiopathic Parkinson’s disease. This article presents a validated version in German. Method: The German translation was adapted interculturally and developed using an internationally recognized procedure in consultation with the authors of the original publication. The primary text was first translated by two bilingual neuroscientists independently of one another. Thereafter, the two versions were collated to generate a consensus version, which was accepted by the translators and preliminarily trialled with 10 patients. Hereafter, the German version was re-translated back into English by two other neurologists, again independently of one another, and a final consensus was agreed on using these versions. This English version was then compared with the original text by all of the translators, a process which entailed as many linguistic modifications to the German version as the translators considered necessary to generate a linguistically acceptable German version that was as similar as possible to the original English version. After this test text had been subsequently approved by the authors, the German text was applied to 50 patients in two hospitals, and reviewed as to its practicability and comprehensibility. Results: This work led to the successful creation of an inter-culturally adapted and linguistically validated German version of the KPPS. Discussion: The German version presented here is a useful scare for recording and quantifying pain in empirical studies, as well as in clinical practice.
|
|
| 32. |
- Kader, M., et al.
(author)
-
Mobility device use in people with Parkinson's disease : A 3-year follow-up study
- 2018
-
In: Acta Neurologica Scandinavica. - : Hindawi Limited. - 0001-6314. ; 138:1, s. 70-77
-
Journal article (peer-reviewed)abstract
- Objectives: This study aimed to investigate how the use and perceived unmet need of mobility devices (MD) in people with Parkinson's disease (PD) evolve over a 3-year period. Methods: The study reports baseline assessments (n = 255) and comparisons for participants with complete data at baseline and the 3-year follow-up (n = 165). Structured questions addressed the use and perceived unmet need of various MDs indoor and outdoor (eg, canes, wheeled walkers, and manual and powered wheelchairs). McNemar tests were used to investigate differences over time. Results: In the total sample at baseline, 30% and 52% of the participants reported using MDs indoors and outdoors, respectively. Among those with complete data also at the 3-year follow-up, the proportion of participants using MDs increased significantly (P < .001) from 22% to 40% for indoors and from 48% to 66% for outdoors, with transition of MD toward more assistive potential (ie, wheeled walker and manual wheelchair). Wheeled walkers were the most commonly used MD indoors as well as outdoors on both occasions. Among the users of multiple MDs, the most common combination was cane and wheeled walker on both occasions. The proportion of participants who reported a perceived unmet need of MDs was 5% at baseline, whereas it was 21%, 3 years later. Conclusions: The use and perceived unmet need of MDs in people with PD increase over time. There is a need for addressing MDs at clinical follow-ups of people with PD, with continuous attention in primary health care and municipality contexts.
|
|
| 33. |
- Klingelhoefer, L., et al.
(author)
-
Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest) zur Erhebung nichtmotorischer Symptome bei Dystonie : Interkulturelle Adaptation in deutscher Sprache
- 2020
-
In: Nervenarzt. - : Springer Science and Business Media LLC. - 0028-2804. ; 91, s. 337-342
-
Journal article (peer-reviewed)abstract
- Background: Non-motor symptoms (NMS) in patients with dystonia have a relevant impact on health-related quality of life; however, a comprehensive easy to use NMS assessment tool for clinical bedside use is currently not available. Objective: The validated German version of the dystonia non-motor symptoms questionnaire (DNMSQuest) for assessing NMS in craniocervical dystonia is presented. Methods: The DNMSQuest in the German language was developed based on internationally recognized standards for intercultural adaptation of self-completed patient questionnaires. Translation of the original English questionnaire into the German language as well as back translation to English was carried out independently by four bilingual specialists in neurological movement disorders. In each case a consensus version accepted by each translator was created by another neurologist. The back translated English version was compared with the original English questionnaire for relevant linguistic and content discrepancies by a neurologist who was significantly involved in the development of the original questionnaire. The final German version was used in 130 patients with cervical dystonia and 48 healthy controls in an international, multicenter validation study. Results: An interculturally adapted validated version of the DNMSQuest in the German and English languages was developed for rapid bedside assessment and evaluation of NMS in cervical dystonia. Conclusion: The DNMSQuest successfully bridges the current gap of a validated disease-specific, patient self-administered, short, comprehensive questionnaire for NMS assessment in routine clinical practice in craniocervical dystonia. It is envisaged that this tool will be useful for the clinical practice and trials.
|
|
| 34. |
- Lindvall, O, et al.
(author)
-
Transplantation of fetal dopamine neurons in Parkinson's disease : one-year clinical and neurophysiological observations in two patients with putaminal implants
- 1992
-
In: Annals of Neurology. - : Wiley. - 0364-5134 .- 1531-8249. ; 31:2, s. 65-155
-
Journal article (peer-reviewed)abstract
- Ventral mesencephalic tissue from aborted human fetuses (age, 6-7 weeks' postconception) was implanted unilaterally into the putamen using stereotaxic surgery in 2 immunosuppressed patients (Patients 3 and 4 in our series) with advanced idiopathic Parkinson's disease. Tissue from 4 fetuses was grafted to each patient. Compared with our previous 2 patients, the following changes in the grafting procedure were introduced: the implantation instrument was thinner, more tissue was placed in the operated structure, and the time between abortion and grafting was shorter. There were no postoperative complications. Both patients showed a gradual and significant amelioration of parkinsonian symptoms (most marked in Patient 3) starting at 6 and 12 weeks after grafting, respectively, reaching maximum stability at approximately 4 to 5 months; patients remained relatively stable thereafter during the 1-year follow-up period. Clinical improvement was observed as a reduction of the time spent in the "off" phase and the number of daily "off" periods; a lessening of bradykinesia and rigidity during the "off" phase, mainly but not solely on the side contralateral to the graft; and a prolongation and change in the pattern of the effect of a single dose of L-dopa. Neurophysiological measurements revealed a more rapid performance of simple and complex arm and hand movements bilaterally, but primarily contralateral to the graft. The results indicate that patients with Parkinson's disease can show significant and sustained improvement of motor function after intrastriatal implantation of fetal dopamine-rich mesencephalic tissue. The accompanying paper by Sawle and colleagues describes the results of repeated positron emission tomography scans in these patients.
|
|
| 35. |
- Odin, Giliane P., et al.
(author)
-
Experimental degradation of helicoidal photonic nanostructures in scarab beetles (Coleoptera: Scarabaeidae): implications for the identification of circularly polarizing cuticle in the fossil record
- 2018
-
In: Journal of the Royal Society Interface. - : ROYAL SOC. - 1742-5689 .- 1742-5662. ; 15:148
-
Journal article (peer-reviewed)abstract
- Scarab beetles (Coleoptera: Scarabaeidae) can exhibit striking colours produced by pigments and/or nanostructures. The latter include helicoidal (Bouligand) structures that can generate circularly polarized light. These have a cryptic evolutionary history in part because fossil examples are unknown. This suggests either a real biological signal, i.e. that Bouligand structures did not evolve until recently, or a taphonomic signal, i.e. that conditions during the fossilization process were not conducive to their preservation. We address this issue by experimentally degrading circularly polarizing cuticle of modern scarab beetles to test the relative roles of decay, maturation and taxonomy in controlling preservation. The results reveal that Bouligand structures have the potential to survive fossilization, but preservation is controlled by taxonomy and the diagenetic history of specimens. Further, cuticle of specific genus (Chrysina) is particularly decay-prone in alkaline conditions; this may relate to the presence of certain compounds, e. g. uric acid, in the cuticle of these taxa.
|
|
| 36. |
|
|
| 37. |
- Odin, Per, et al.
(author)
-
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
- 2015
-
In: Parkinsonism & Related Disorders. - : Elsevier BV. - 1873-5126 .- 1353-8020. ; 21:10, s. 1133-1144
-
Research review (peer-reviewed)abstract
- Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are: • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is <4 years. • Cognitive decline related to non-motor fluctuations is an indication for device-aided therapies. If cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent with device-aided therapies. • Insufficient control of motor complications (or drug-resistant tremor in the case of DBS) are indications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged >70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.
|
|
| 38. |
- Othberg, A, et al.
(author)
-
Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro
- 1995
-
In: Experimental Brain Research. - 0014-4819. ; 105:1, s. 22-111
-
Journal article (peer-reviewed)abstract
- The neurotrophic effects of the BB isoform of platelet-derived growth factor (PDGF) on rat and human fetal mesencephalic dopaminergic neurons have been characterized in vitro. A dose-response analysis demonstrated maximal responses at 30 ng/ml of PDGF-BB. This concentration resulted in a marked increase in the survival and neurite outgrowth from rat and human tyrosine hydroxylase-(TH) positive, presumed dopaminergic neurons after 7 days in vitro. The effects of PDGF-BB on survival of TH-positive neurons were comparable to those of brain-derived neurotrophic factor (BDNF), whereas neurite outgrowth was more pronounced after addition of BDNF. The combination of BDNF and PDGF-BB yielded no additive effects. Double immunohistochemical staining of rat cultures demonstrated PDGF beta-receptors on about 90% of the TH-positive neurons. PDGF-BB treatment of rat mesencephalic cultures induced an upregulation of c-fos and TH mRNA with maximal levels after 0.5-2 h as assessed by quantitative PCR analysis. An increased number of Fos protein-positive cells was detected immunohistochemically after 4 h of PDGF-BB treatment. The present results provide further evidence for specific and direct effects of PDGF-BB on gene expression, survival and neurite outgrowth of mesencephalic dopaminergic neurons of rat and human origin.
|
|
| 39. |
- Persson, Carina, 1964, et al.
(author)
-
From Molecular Oxygen to Primordial Molecules with the Odin Satellite
- 2008
-
In: Proceedings in Astronomical Society of the Pacific Conference Series "Frontiers of Astronomy", NRAO 50th Anniversary Science Symposium, eds. A. Bridle, J. Condon and G. Hunt.. - 9781583816608 ; 395, s. 378-
-
Conference paper (other academic/artistic)abstract
- Odin is a mm/submm-wave-spectroscopy Astronomy and Aeronomy satellite. Its design life time was two years, but it has now operated successfully for more than six years. Its 1.1 m high-precision telescope, with a beam efficiency of 90%, has beamwidths of 10 arcmin and 2 arcmin at mm and submm wavelengths, respectively. It is equipped with a cryogenic receiver package of four tunable, SSB, submm Schottky mixers covering the 486-504 and 541-581 GHz frequency range, and a fixed-tuned HEMT receiver at a frequency of 118-119 GHz.Odin has discovered the elusive oxygen (O2) molecule at 119 GHz - the detection was made in the ρ Oph A molecular-cloud core. The O2 abundance, X(O2), is ≈5×10^{-8} - Larsson et al. (2007: A&A, 466, 999). Odin has also discovered water (H2O) at 557 GHz in the core of the Milky Way Galaxy - the Sgr A CircumNuclear Disk (CND)- and mapped its distribution in the Sgr A Complex including the +20 and +50 km s-1 Molecular Clouds - Sandqvist et al. (2006: J.Phys. Conf.Ser., 54, 72). Furthermore, devoting about 1,100 orbits (each of which contains 1 hour of observable astronomy time) Odin has performed a spectral-line survey of Orion KL in the ranges 487-492 and 542-577 GHz. There are 280 identified spectral lines from 38 species and 64 unidentified lines [Olofsson et al. (2007: A&A, 476, 791) and Persson et al. (2007: A&A, 476, 807)].Odin has searched for emission from the 557 GHz ortho-H2O line in six nearby starburst galaxies yielding three-sigma upper limits to the water abundance relative to H2 (NGC253 -
|
|
| 40. |
- Pietz, Katja, et al.
(author)
-
Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up
- 1998
-
In: Journal of Neurology, Neurosurgery and Psychiatry. - 1468-330X. ; 65:5, s. 709-716
-
Journal article (peer-reviewed)abstract
- OBJECTIVES: Despite the recent introduction of new peroral drugs as well as neurosurgical methods for Parkinson's disease, treatment of late stage parkinsonian patients remains difficult and many patients become severely handicapped because of fluctuations in their motor status. Injections and infusions of apomorphine has been suggested as an alternative in the treatment of these patients, but the number of studies describing the effects of such a treatment over longer time periods is still limited. The objective was to investigate the therapeutic response and range of side effects during long term treatment with apomorphine in advanced Parkinson's disease. METHODS: Forty nine patients (30 men, 19 women; age range 42-80 years) with Parkinson's disease were treated for 3 to 66 months with intermittent subcutaneous injections or continuous infusions of apomorphine. RESULTS: Most of the patients experienced a long term symptomatic improvement. The time spent in "off" was significantly reduced from 50 to 29.5% with injections and from 50 to 25% with infusions of apomorphine. The quality of the remaining "off" periods was improved with infusion treatment, but was relatively unaffected by apomorphine injections. The overall frequency and intensity of dyskinesias did not change. The therapeutic effects of apomorphine were stable over time. The most common side effect was local inflammation at the subcutaneous infusion site, whereas the most severe were psychiatric side effects occurring in 44% of the infusion and 12% of the injection treated patients. CONCLUSION: Subcutaneous apomorphine is a highly effective treatment which can substantially improve the symptomatology in patients with advanced stage Parkinson's disease over a prolonged period of time.
|
|
